How to cite item

KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

   
@article{TLCR30505,
	author = {Amy Lauren Cummings and Edward B. Garon},
	title = {KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit},
	journal = {Translational Lung Cancer Research},
	volume = {8},
	number = {Suppl 4},
	year = {2019},
	keywords = {},
	abstract = {The past two years have been exceptional for pembrolizumab in advanced non-small cell lung cancer (NSCLC). The publication of KEYNOTE-189 redefined first-line treatment with combination chemotherapy and pembrolizumab as a new standard-of-care in an unselected population, KEYNOTE-042 expanded the United States Food & Drug Administration (FDA)’s approval for first-line pembrolizumab monotherapy, and KEYNOTE-001 showed the most robust five-year overall survival (OS) results ever seen in advanced NSCLC, specifically among patients with high programmed cell death ligand 1 (PD-L1) expression (Table 1) (1-4).},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/30505}
}